Can siRNA Technology Provide the Tools for Gene Therapy of the Future?
Authors: Racz, Zs1; Hamar, P.1
Source: Current Medicinal Chemistry, Volume 13, Number 19, August 2006 , pp. 2299-2307(9)
Publisher: Bentham Science Publishers
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
A new era in genetics has started 15 years ago, when co-suppression in petunia has been discovered. Later, co-suppression was identified as RNA interference (RNAi) in many plant and lower eukaryote animals. Although an ancient antiviral host defense mechanism in plants, the physiologic role of RNAi in mammals is still not completely understood. RNAi is directed by short interfering RNAs (siRNAs), one subtype of short double stranded RNAs. In this review we summarize the history and mechanisms of RNAi. We also aim to highlight the correlation between structure and efficacy of siRNAs. Delivery is the most important obstacle for siRNA based gene therapy. Viral and nonviral deliveries are discussed. In vivo delivery is the next obstacle to clinical trials with siRNAs. Although hydrodynamic treatment is effective in animals, it cannot be used in human therapy. One possibility is organ selective catheterization. The known side effects of synthesized siRNAs are also discussed. Although there are many problems to face in this new field of gene therapy, successful in vitro and in vivo experiments raise hope for treating human disease with siRNA.Keywords: RNA interference (RNAi); short interfering RNA (siRNA); delivery; human gene therapy
Document Type: Research article
DOI: 10.2174/092986706777935186
Affiliations: 1: Institute of Pathophysiology, Semmelweis University of Medicine, H-1089 Budapest Nagyvarad ter 4, Hungry.
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help